Es gab 50 kürzliche Insider-Transaktionen für Sigilon Therapeutics, Inc. (SGTX), darunter 33 Käufe und 15 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $29.49M und die gesamten Insider-Verkäufe auf $3.07M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Oesterle Stephen N., Ruffolo Robert R, Cole Douglas G.. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — SGTX
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2023-08-11 |
Oesterle Stephen N. |
Director |
Aktienrückgabe |
4,273 |
$7.41 |
$31.66K |
- |
| 2023-08-11 |
Ruffolo Robert R |
Director |
Aktienrückgabe |
3,754 |
$7.41 |
$27.82K |
- |
| 2023-08-11 |
Cole Douglas G. |
Director |
Aktienrückgabe |
683 |
$8.28 |
$5.65K |
- |
| 2023-08-11 |
Cox John |
Director |
Aktienrückgabe |
683 |
$9.92 |
$6.78K |
- |
| 2023-08-11 |
Vivaldi Coelho Rogerio |
President and CEO |
Aktienrückgabe |
35,382 |
$14.17 |
$501.36K |
- |
| 2023-08-11 |
Shaff Eric D. |
Director |
Aktienrückgabe |
683 |
$9.92 |
$6.78K |
- |
| 2023-08-11 |
Patel Kavita |
Director |
Aktienrückgabe |
683 |
$9.92 |
$6.78K |
- |
| 2023-08-11 |
Kowalsky Matthew Paul |
Chief of Staff and CLO |
Aktienrückgabe |
1,925 |
$14.92 |
$28.72K |
- |
| 2023-08-11 |
Ashton-rickardt Philip |
Chief Scientific Officer |
Aktienrückgabe |
8,845 |
$14.17 |
$125.33K |
- |
| 2023-08-11 |
Pontes Josias |
Chief Financial Officer |
Aktienrückgabe |
10,767 |
$14.17 |
$152.57K |
- |
| 2023-08-11 |
Yuan Qing Sarah |
Ctoo |
Aktienrückgabe |
8,846 |
$14.17 |
$125.35K |
- |
| 2023-08-11 |
Eli Lilly & Co |
10 Percent Owner |
Informierter Kauf |
1,718,493 |
$14.92 |
$25.64M |
100 |
| 2023-08-11 |
Flagship Ventures Fund V General Partner Llc |
10 Percent Owner |
Übernahmeangebot (Verkauf) |
113,960 |
$14.92 |
$1.7M |
- |
| 2023-07-27 |
Yuan Qing Sarah |
Ctoo |
Optionsausübung |
2,884 |
$19.24 |
$55.49K |
2,884 |
| 2023-07-21 |
Vivaldi Coelho Rogerio |
President and CEO |
Optionsausübung |
5,528 |
$19.24 |
$106.36K |
11,963 |
| 2023-07-21 |
Pontes Josias |
Chief Financial Officer |
Optionsausübung (Verkauf) |
1,444 |
$19.24 |
$27.78K |
3,171 |
| 2023-06-28 |
Eli Lilly & Co |
10 Percent Owner |
Veräußerung |
- |
- |
- |
211,110 |
| 2023-05-19 |
Oesterle Stephen N. |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-05-19 |
Ruffolo Robert R |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-05-19 |
Cole Douglas G. |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-05-19 |
Cox John |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-05-19 |
Shaff Eric D. |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-05-19 |
Patel Kavita |
Director |
RSU-Zuteilung |
8,888 |
$0.64 |
$5.66K |
8,888 |
| 2023-02-28 |
Vivaldi Coelho Rogerio |
President and CEO |
RSU-Zuteilung |
460,000 |
$1.09 |
$501.4K |
460,000 |
| 2023-02-28 |
Kowalsky Matthew Paul |
Chief of Staff and CLO |
Veräußerung |
77,777 |
$4.12 |
$320.44K |
- |
| 2023-02-28 |
Kowalsky Matthew Paul |
Chief of Staff and CLO |
RSU-Zuteilung |
165,000 |
$1.09 |
$179.85K |
165,000 |
| 2023-02-28 |
Ashton-rickardt Philip |
Chief Scientific Officer |
RSU-Zuteilung |
115,000 |
$1.09 |
$125.35K |
115,000 |
| 2023-02-28 |
Pontes Josias |
Chief Financial Officer |
RSU-Zuteilung |
140,000 |
$1.09 |
$152.6K |
140,000 |
| 2023-02-28 |
Yuan Qing Sarah |
Ctoo |
RSU-Zuteilung |
115,000 |
$1.09 |
$125.35K |
115,000 |
| 2022-05-26 |
Oesterle Stephen N. |
Director |
RSU-Zuteilung |
8,888 |
- |
- |
8,888 |
| 2022-05-26 |
Ruffolo Robert R |
Director |
RSU-Zuteilung |
8,888 |
- |
- |
8,888 |
| 2022-05-26 |
Cole Douglas G. |
Director |
RSU-Zuteilung |
8,888 |
$0.76 |
$6.78K |
8,888 |
| 2022-05-26 |
Cox John |
Director |
RSU-Zuteilung |
8,888 |
$0.76 |
$6.78K |
8,888 |
| 2022-05-26 |
Shaff Eric D. |
Director |
RSU-Zuteilung |
8,888 |
$0.76 |
$6.78K |
8,888 |
| 2022-05-26 |
Patel Kavita |
Director |
RSU-Zuteilung |
8,888 |
$0.76 |
$6.78K |
8,888 |
| 2022-05-26 |
Story Brooke |
Director |
RSU-Zuteilung |
8,888 |
- |
- |
8,888 |
| 2022-04-01 |
Yuan Qing Sarah |
Ctoo |
RSU-Zuteilung |
120,000 |
- |
- |
120,000 |
| 2022-03-07 |
Yuan Qing Sarah |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2022-02-18 |
Vivaldi Coelho Rogerio |
President and CEO |
RSU-Zuteilung |
230,000 |
$1.48 |
$340.4K |
230,000 |
| 2022-02-18 |
Ashton-rickardt Philip |
Chief Scientific Officer |
RSU-Zuteilung |
90,000 |
$1.48 |
$133.2K |
90,000 |
| 2022-02-18 |
Pontes Josias |
Acting Chief Financial Office |
RSU-Zuteilung |
60,000 |
$1.48 |
$88.8K |
60,000 |
| 2022-02-18 |
Orfali May |
Chief Medical Officer |
RSU-Zuteilung |
10,000 |
$1.48 |
$14.8K |
10,000 |
| 2022-01-03 |
Vivaldi Coelho Rogerio |
President and CEO |
RSU-Zuteilung |
400,000 |
$3.03 |
$1.21M |
400,000 |
| 2022-01-03 |
Ashton-rickardt Philip |
Chief Scientific Officer |
RSU-Zuteilung |
90,000 |
$3.03 |
$272.7K |
90,000 |
| 2022-01-03 |
Pontes Josias |
VP, Head of Finance |
RSU-Zuteilung |
65,000 |
$3.03 |
$196.95K |
65,000 |
| 2022-01-03 |
Orfali May |
Chief Medical Officer |
RSU-Zuteilung |
10,000 |
$3.03 |
$30.3K |
10,000 |
| 2021-12-01 |
Orfali May |
Chief Medical Officer |
RSU-Zuteilung |
80,000 |
$3.14 |
$251.2K |
80,000 |
| 2021-11-29 |
Orfali May |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2021-11-04 |
Vivaldi Coelho Rogerio |
President and CEO |
RSU-Zuteilung |
50,000 |
- |
- |
73,461 |
| 2021-09-30 |
Pontes Josias |
VP, Head of Finance |
RSU-Zuteilung |
11,500 |
- |
- |
13,339 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
